Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISINE vs NAPHAZOLINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
Relief of ocular redness due to minor irritations,Off-label: symptomatic treatment of allergic conjunctivitis
Ocular: relief of redness, itching, and irritation due to minor eye irritations or allergic conjunctivitis. Nasal: temporary relief of nasal congestion due to colds, allergies, or sinusitis.
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life.
Not systemically absorbed; no significant metabolism occurs in the eye.
Not extensively studied; likely hepatic metabolism via unknown enzymes.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine.
Approximately 80% bound to plasma proteins, primarily albumin
Not well characterized; expected to be low (<20%) based on structural analogs.
Not clinically significant for topical ophthalmic use; systemic Vd estimated at 0.5-1 L/kg based on IV data
Not established in humans; based on animal data, approximately 0.5-1.0 L/kg, suggesting distribution into total body water.
Ocular: negligible systemic bioavailability (<1% from topical dose); oral not applicable
Ophthalmic and intranasal: low systemic bioavailability due to local vasoconstriction limiting absorption; exact % not determined, estimated <1%.
No dose adjustment required; systemic absorption is minimal.
No dose adjustment required; primarily locally acting with minimal systemic absorption.
No dose adjustment required; systemic absorption is minimal.
No dose adjustment required; use caution in severe hepatic impairment due to potential for systemic effects.
Children 6 years and older: 1 drop in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily. Safety and efficacy in children under 6 years not established.
Children ≥6 years: 1-2 drops of 0.1% ophthalmic solution every 6-8 hours; nasal spray 0.05% for children ≥6 years, 1 spray per nostril every 8-10 hours. Contraindicated in infants and children <6 years due to risk of CNS depression.
No specific dose adjustment, but use with caution due to increased risk of systemic effects (e.g., hypertension, cardiac arrhythmias) and potential for angle-closure glaucoma.
Elderly patients may be more sensitive to adverse effects (e.g., rebound congestion, hypertension); use lowest effective dose and shortest duration. Avoid in patients with cardiovascular disease or glaucoma.
None
None
Do not use in patients with narrow-angle glaucoma; overuse may cause rebound hyperemia; avoid in children under 6 years; discontinue if eye pain or vision changes occur.
Prolonged use may cause rebound congestion (rhinitis medicamentosa). Use with caution in patients with cardiovascular disease (hypertension, arrhythmias), hyperthyroidism, diabetes, or prostatic hyperplasia. Avoid use in patients with narrow-angle glaucoma. Do not exceed recommended dosage or duration.
Hypersensitivity to tetrahydrozoline or any component; narrow-angle glaucoma; concurrent use with MAO inhibitors
Hypersensitivity to naphazoline or any component. Narrow-angle glaucoma (ophthalmic use). Use with MAO inhibitors or within 14 days of stopping therapy (risk of hypertensive crisis).
No known food interactions. Avoid alcohol as it may exacerbate eye redness or irritation.
No significant food interactions; avoid excessive caffeine or other stimulants as they may potentiate sympathomimetic effects.
No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. Second and third trimesters: no specific risks identified. However, avoid prolonged use due to potential vasoconstrictive effects.
Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks include vasoconstriction and reduced uterine blood flow. No adequate and well-controlled studies in pregnant women. Animal studies have not been reported. First trimester: No known teratogenic effects. Second and third trimesters: Potential risk of reduced uteroplacental perfusion when used systemically; topical use at recommended doses unlikely to cause significant effects. Overall, classified as FDA Pregnancy Category C. Caution is advised.
Negligible systemic absorption with topical ocular use; M/P ratio not determined. Excretion into breast milk unlikely. Considered compatible with breastfeeding; use caution with excessive or prolonged use.
Excretion in human milk is unknown. Due to low systemic absorption after topical application, amounts ingested by an infant are expected to be minimal. No known adverse effects in nursing infants. M/P ratio not reported. Consider benefit of treatment versus potential risk to infant. Use caution and avoid prolonged or excessive dosing.
No dose adjustments necessary for pregnancy as systemic absorption is negligible. Standard dosing (1-2 drops every 8-12 hours) applies. Avoid overuse due to potential for rebound congestion or systemic effects.
No dose adjustments required for topical ocular or nasal use due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not significant for topical administration. Use at standard recommended doses and avoid prolonged or excessive application.
Visine (tetrahydrozoline) is a topical ocular decongestant; prolonged use (>72 hours) can cause rebound hyperemia and conjunctivitis medicamentosa. Avoid in patients with narrow-angle glaucoma, cardiovascular disease, or hypertension. Do not use in children under 2 years without medical advice.
Naphazoline is a direct-acting sympathomimetic with rapid onset; use limited to 3-5 days to avoid rebound congestion and rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma due to potential mydriasis. Caution in cardiovascular disease, hypertension, and hyperthyroidism; may elevate BP and cause palpitations. Not for use in infants or children under 6 years due to risk of CNS depression.
Do not use Visine for more than 3 days to avoid rebound redness.,Remove contact lenses before instilling drops and wait at least 15 minutes before reinserting.,Do not share the bottle to prevent infection.,Avoid touching the dropper tip to any surface or the eye.,If eye pain, vision changes, or persistent redness occur, discontinue use and consult a doctor.
Do not use for more than 3-5 consecutive days to avoid worsening congestion and dependence.,Avoid contact with eyes; if eye contact occurs, flush with water for 15 minutes.,Do not share the bottle with others to prevent infection spread.,Store at room temperature, away from light and moisture.,Consult a doctor before use if you have heart disease, high blood pressure, or an enlarged prostate.
No interactions on record
"Naphazoline, an alpha-1 adrenergic receptor agonist, induces vasoconstriction and elevates blood pressure. Co-administration with ergometrine, an ergot alkaloid that also causes potent vasoconstriction via serotonin and alpha-adrenergic receptor activation, results in additive or synergistic hypertensive effects. This combination significantly increases the risk of severe hypertension, hypertensive crisis, and potential end-organ damage such as stroke or myocardial ischemia."
"Naphazoline, an alpha-adrenergic agonist, can cause systemic vasoconstriction and reflex bradycardia. When combined with nadolol, a non-selective beta-blocker, the bradycardic effects may be additive, leading to an increased risk of atrioventricular (AV) block. This interaction can result in profound bradycardia, hypotension, and potential syncope, particularly in patients with pre-existing cardiac conduction abnormalities."
"Naphazoline, an alpha-adrenergic agonist with vasoconstrictive properties, can increase systemic blood pressure through peripheral vasoconstriction, which may counteract the antihypertensive effects of cyclobenzaprine, a centrally acting muscle relaxant that can lower blood pressure due to its sedative and alpha-blocking activities. This pharmacodynamic opposition may reduce the efficacy of cyclobenzaprine in managing hypertension or lead to inadequate blood pressure control. Clinically, patients may experience elevated blood pressure readings or require dose adjustments of antihypertensive therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISINE vs NAPHAZOLINE HYDROCHLORIDE, answered by our medical review team.
VISINE is a Ophthalmic Decongestant that works by Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.. NAPHAZOLINE HYDROCHLORIDE is a Ophthalmic Decongestant that works by Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISINE and NAPHAZOLINE HYDROCHLORIDE depend on the specific clinical indication. These are both Ophthalmic Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISINE is: 1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.. The standard adult dose of NAPHAZOLINE HYDROCHLORIDE is: 1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISINE and NAPHAZOLINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISINE is classified as Category C. No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. S. NAPHAZOLINE HYDROCHLORIDE is classified as Category C. Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.